Complicated Intra-Abdominal Infections - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 57 pages report, published by Global Markets Direct

Keywords : Complicated Intra-Abdominal Infections Therapeutic Products under Development, Key Players in Complicated Intra-Abdominal Infections Therapeutics, Complicated Intra-Abdominal Infections Pipeline Overview, Complicated Intra-Abdominal Infections Pipeline, Complicated Intra-Abdominal Infections Pipeline Assessment

Report ThumbnailSeptember-2013
Complicated Intra-Abdominal Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Complicated Intra-Abdominal Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections. Complicated Intra-Abdominal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Complicated Intra-Abdominal Infections.
- A review of the Complicated Intra-Abdominal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Complicated Intra-Abdominal Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Complicated Intra-Abdominal Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Complicated Intra-Abdominal Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Complicated Intra-Abdominal Infections, H2 2013 7
  • Products under Development for Complicated Intra-Abdominal Infections - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Combination Products, H2 2013 24
  • Assessment by Route of Administration, H2 2013 25
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Molecule Type, H2 2013 27
  • Assessment by Stage and Molecule Type, H2 2013 28
  • List of Tables
  • Number of Products Under Development for Complicated Intra-Abdominal Infections, H2 2013 7
  • Products under Development for Complicated Intra-Abdominal Infections - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • AstraZeneca PLC, H2 2013 16
  • Merck & Co., Inc., H2 2013 17
  • Rib-X Pharmaceuticals, Inc., H2 2013 18
  • Cubist Pharmaceuticals, Inc., H2 2013 19
  • MerLion Pharmaceuticals Pte Ltd, H2 2013 20
  • Atox Bio Inc., H2 2013 21
  • Tetraphase Pharmaceuticals Inc., H2 2013 22
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Combination Products, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 28
  • Complicated Intra-Abdominal Infections Therapeutics - Drug Profile Updates 41
  • Complicated Intra-Abdominal Infections Therapeutics - Discontinued Products 49
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Complicated Intra-Abdominal Infections Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Complicated Intra-Abdominal Infections 7
  • Complicated Intra-Abdominal Infections Therapeutics under Development by Companies 9
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Complicated Intra-Abdominal Infections Therapeutics - Products under Development by Companies 15
  • Companies Involved in Complicated Intra-Abdominal Infections Therapeutics Development 16
  • AstraZeneca PLC 16
  • Merck & Co., Inc. 17
  • Rib-X Pharmaceuticals, Inc. 18
  • Cubist Pharmaceuticals, Inc. 19
  • MerLion Pharmaceuticals Pte Ltd 20
  • Atox Bio Inc. 21
  • Tetraphase Pharmaceuticals Inc. 22
  • Complicated Intra-Abdominal Infections - Therapeutics Assessment 23
  • Assessment by Monotherapy Products 23
  • Assessment by Combination Products 24
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Drug Profiles 29
  • delafloxacin - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • (ceftolozane + tazobactam) - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • eravacycline - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • (ceftazidime + avibactam) - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • MK-7655 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • ceftriaxone sodium CR - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Complicated Intra-Abdominal Infections Therapeutics - Drug Profile Updates 41
  • Complicated Intra-Abdominal Infections Therapeutics - Discontinued Products 49
  • Complicated Intra-Abdominal Infections - Product Development Milestones 50
  • Featured News & Press Releases 50
  • Jul 15, 2013: FDA Grants QIDP Designation to Eravacycline, Tetraphase's Lead Antibiotic Product Candidate 50
  • May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 50
  • Jan 07, 2013: Cubist Pharma Provides Update On Infectious Disease Drug Candidate, Ceftolozane 51
  • Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 51
  • Sep 12, 2012: Tetraphase Pharma Announces Positive Phase II Data For Eravacycline In Patients With Complicated Intra-Abdominal Infections 52
  • Sep 05, 2012: Tetraphase Pharma To Present New Clinical And Preclinical Research On Antibiotic Portfolio At ICAAC 2012 53
  • Dec 13, 2011: Cubist Announces First Patient Dosed In Pivotal Global Phase III Trial Of CXA-201 For Complicated Intra-Abdominal Infections 53
  • Jun 16, 2005: FDA Approves Tygacil, First-in-class Antibiotic 54
  • Jan 28, 2005: FDA Grants Tygacil (Tigecycline) NDA Priority Review Status 54
  • Appendix 56
  • Methodology 56
  • Coverage 56
  • Secondary Research 56
  • Primary Research 56
  • Expert Panel Validation 56
  • Contact Us 57
  • Disclaimer 57

Please select a license type

Share

Related Products

Global Markets DirectComplicated Intra-Abdominal Infections - Pipeline Review, H2 2013Product ThumbnailComplicated Intra-Abdominal Infections - Pipeline Review, H2 2013, Industry ReportProduct #: 113333
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved